Related Experiment Video
Updated: Jul 14, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Optimal and minimax three-stage designs for phase II oncology clinical trials
1Global Biometric Science, Pharmaceutical Research Institute, Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA. kun.chen@bms.com
Abstract:
The common objective of oncology phase II trials is to evaluate the anti-tumor activity of a new agent and to determine whether the new drug warrants further investigation. For cancer drugs that significantly shrink tumors, response (CR and PR) rate is usually the primary endpoint in cancer phase II trials for testing H(0): P
More Related Videos
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Dosage Regimens: Designs and Approaches
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Methods of Medium Optimization